What's Happening?
Nuclera has introduced a nanodisc panel designed to streamline the production of G-protein coupled receptors (GPCRs), a critical target in drug discovery. The panel, part of the eProtein Discovery™ workflow, includes a GPCR screen kit and scale-up reagents,
allowing researchers to produce active GPCRs in 48 hours. This innovation addresses the challenges of obtaining purified, stable, and functional GPCRs, which are crucial for pharmacology and drug discovery. The nanodisc panel minimizes variability associated with traditional membrane protein production methods, providing a soluble membrane bilayer that maintains structural integrity and functionality.
Why It's Important?
GPCRs are a major target for drug development, with one-third of FDA-approved drugs acting on these receptors. However, traditional methods of producing GPCRs often result in proteins adopting non-native conformations. Nuclera's nanodisc panel offers a more efficient and reliable approach, potentially accelerating drug discovery and development processes. By providing a fast-track route to purified, active GPCRs, this innovation could lead to the development of new therapies for a range of diseases, benefiting both researchers and patients.
